BC
IONS icon

Bayforest Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Bayforest Capital’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-413
Closed -$31K – 1073
2026
Q1 		$31K Sell
413
-678
-62% -$53.5K 0.03% 667
2025
Q4 		$86.3K Buy
1,091
+937
+608% +$70.6K 0.06% 502
2025
Q3 		$10.1K Buy
+154
New +$7.52K ﹤0.01% 670

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Bayforest Capital's IONS Position: Q2 2026 in Review

Bayforest Capital sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 413 shares — an estimated $31K sold.

Bayforest Capital first reported a position in IONS in Q3 2025 and held it in 3 quarters. The position peaked at $86.3K in Q4 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Bayforest Capital reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Bayforest Capital sold 413 Ionis Pharmaceuticals shares in Q2 2026, an estimated $31K.
  • Bayforest Capital first reported a position in Ionis Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Bayforest Capital's Ionis Pharmaceuticals position peaked at $86.3K in Q4 2025.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.